Zafgen has something to cheer as diabetes drug makes the cut in PhII study
After being plagued by a laundry list of setbacks that culminated in the desertion of its obesity drug and the departure of its CEO, Zafgen finally has some good news to report. Data from a cohort of a mid-stage study suggested that its now-lead diabetes drug induced statistically significant improvements in blood sugar levels and weight loss.
The Boston-based company’s shares $ZFGN rose about 7% in pre-market trading on Thursday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.